Request Demo

Last update 24 Apr 2026

Baclofen

Last update 24 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryBaclofen, sold under the brand name Lioresal among others, is a medication used to treat muscle spasticity such as from a spinal cord injury or multiple sclerosis. It may also be used for hiccups and muscle spasms near the end of life. It is taken by mouth or by delivery into the spinal canal. Common side effects include sleepiness, weakness, and dizziness. Serious side effects may occur if baclofen is rapidly stopped including seizures and rhabdomyolysis. Use in pregnancy is of unclear safety while use during breastfeeding is probably safe. It is believed to work by decreasing levels of certain neurotransmitters. Baclofen was approved for medical use in the United States in 1977. It is available as a generic medication.

Drug Type

Small molecule drug

Synonyms

(+-)-Baclofen, 4-Amino-3-(4-chlorophenyl)butyric acid, Baclofen (JP17/USP/INN)

+ [25]

Target

GABAB receptor

Action

agonists

Mechanism

GABAB receptor agonists(Gamma-Aminobutyric Acid B Receptor agonists)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesCongenital Disorders+ [3]

Active Indication

Multiple SclerosisSpinal Cord DiseasesSpinal Cord Injuries+ [4]

Inactive Indication

AlcoholismSpasm

Originator Organization

Novartis Pharma AG

Active Organization

Metacel Pharmaceuticals LLC

Addex Therapeutics Ltd.

Azurity Pharmaceuticals, Inc.

+ [6]

Inactive Organization

Impax Laboratories LLC

UCB, Inc.Strides Pharma International AG

+ [3]

License Organization

Hemony Pharmaceutical Co., Ltd.

Novartis AG

Drug Highest PhaseApproved

First Approval Date

United States (22 Nov 1977),

Spasm

RegulationOrphan Drug (United States), Priority Review (China), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC10H12ClNO2

InChIKeyKPYSYYIEGFHWSV-UHFFFAOYSA-N

CAS Registry1134-47-0

175

Clinical Trials associated with Baclofen

CTIS2023-508143-51-01

/ Active, not recruitingPhase 4IIT

Pulmonary function and sleep related disorders during cervical admission of intrathecal baclofen in spinal cord injury; a safety study

Start Date09 Mar 2026

Sponsor / Collaborator-

NCT05935553

/ RecruitingPhase 2/3IIT

Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence

Benzodiazepines and related molecules are among the most prescribed psychotropic treatments in France and Europe. 13.4% of the French population had at least one reimbursement of benzodiazepines in 2015, which places France second in Europe.
However, the chronic use of benzodiazepines is a source of numerous complications, particularly addictive. To date, there is no authorized pharmacological treatment for benzodiazepine withdrawal.
Baclofen is a gamma-aminobutyric acid (GABA)-B agonist, a pharmacological receptor that regulates GABA-A, the target of benzodiazepines. The pharmacological mechanisms of baclofen are therefore related to those of benzodiazepines. Empirical use outside of the MA has shown that baclofen can facilitate the reduction of benzodiazepines in cases of severe addiction, but this pharmaceutical interest remains to be demonstrated in a comparative study.
The main objective of the project is to evaluate the efficacy of baclofen, compared to placebo, in reducing benzodiazepine doses in patients with benzodiazepine use disorder (BUD).

Start Date15 Jan 2026

Sponsor / Collaborator

Hospices Civils de Lyon

CTIS2024-518822-33-01

/ Not yet recruitingPhase 4

Intrathecal baclofen pump versus selective dorsal rhizotomy for non-ambulatory children with cerebral palsy

Start Date01 Jan 2026

Sponsor / Collaborator

UZ Leuven

100 Clinical Results associated with Baclofen

100 Translational Medicine associated with Baclofen

100 Patents (Medical) associated with Baclofen

8,369

Literatures (Medical) associated with Baclofen

01 Apr 2026·Neurohospitalist

Cardiac Arrest: A Rare Complication of Intrathecal Baclofen Withdrawal

Article

Author: Niraj, Arora ; Karminder, Singh ; Rameez, Merchant ; Chandershekran Prem, Nattanmai

Baclofen, a GABA agonist, is used for the management of spasticity. Intrathecal route is indicated in cases of severe spasticity associated with spinal cord injury. Baclofen withdrawal symptoms can happen after IT pump removal which can present as anxiety, paranoia, psychosis, seizures, hallucinations, severe spasticity and dyskinesia. Cardiac arrest after baclofen withdrawal is rare with only 2 cases in literature so far however in both cases IT-pump was replaced. We present a case of PEA arrest after baclofen IT-pump removal which was managed without replacing. 33 year-old male with history of paraplegia from cervical spinal cord injury (C-6) level, chronic spasticity, fibular osteomyelitis and chronic sacral ulcers presented with wound dehiscence and exposed baclofen pump which was replaced 4 weeks ago due to the end of the pump’s life. After 24–48 h of removal of the baclofen pump, cardiovascular instability in the form of supra ventricular tachycardia with hypotension and altered mentation was noted. It evolved to progressive clinical worsening with stiffness of body, loss of responsiveness, and up-rolling of eyes. Patient underwent PEA, and ROSC after 3 rounds of CPR. He was subsequently intubated, mechanically ventilated and sedated with midazolam intravenously. Baclofen and clonazepam were started through the feeding tube. Over a period of 10 days, midazolam was weaned, and baseline clinical stability was achieved without IT-baclofen pump. Though rare, cardiac arrest can happen after baclofen withdrawal. High index of clinical suspicion is advised for long term baclofen pump patients after pump explant to prevent withdrawal symptoms and complications.

01 Apr 2026·Annals of Physical and Rehabilitation Medicine

Specific procedure combinations in a rehabilitation setting define severity clusters of older adults with multiple sclerosis: a cohort study

Article

Author: Léotard, Antoine ; Bensmail, Djamel ; Joussain, Charles ; Castro, John ; Levy, Jonathan ; Espagnacq, Maude ; Salga, Marjorie ; Leilaz, Arnaud ; Heinzlef, Olivier

INTRODUCTION:

People with multiple sclerosis (PwMS) are ageing and exposed to multiple impairments. We described the use of health care procedures in a physical and rehabilitation medicine setting for PwMS ≥70 years and identified specific participant clusters.

METHODS:

In this observational cohort study using a local data hub (2012 to March 2024), PwMS were identified with ICD-10 codes (G35). An age filter (≥70) was applied. Medical procedures were systematically coded according to a specific French classification over time, including dates of occurrence, and then extracted and grouped by impairment domains: upper motor neuron syndrome and orthopedic deformities (UMN-OD), respiratory and sleep disorders (RSD), and neurogenic lower urinary tract dysfunction (NLUTD). Clinical data were retrospectively collected from medical files. We conducted descriptive analyses and multiple-component and clustering analyses to identify and characterize the participants' profiles.

RESULTS:

Among 206 participants aged 75.7 (4.3) years, 62% (128) were women, 19% (39) had died, and MS had evolved for 43.3 (12.4) years. The Expanded Disability Status Scale (EDSS) was 7.5 (6.5-8.5), and the Charlson Comorbidity Index (CCI) was 6 (5-7). A total of 2794 procedures were performed for 187 participants, mainly in NLUTD (1424 for 170), which was associated with RSD (P = 0.001), but not UMN-OD (P = 0.262). Three groups were identified (Group 1 = isolated NLUTD, Group 2 = RSD and intrathecal baclofen procedures, and Group 3 = no in-hospital management). People in Group 2 had more severe comorbidities (P < 0.001) than those in the other two groups (P = 0.016).

CONCLUSIONS:

In PwMS ≥70 years, the hospital management of MS-related impairments was directly associated with disease severity and overall comorbidities. Participants who were followed only for NLUTD exhibited severity and comorbidity profiles similar to those of participants who did not require hospital procedures.

DATA REGISTRATION:

Our institutional health data warehouse and all derived extracted databases within the scope of the health team perimeter are approved by the French Data Protection Authority under the No. 1980120.

01 Apr 2026·PEDIATRIC NEUROLOGY

Intrathecal Baclofen Therapy in Children: Testing, Dose-Finding, and Complications—A Single-Center Experience

Article

Author: Joubaud, Flora ; Mietton, Claire ; Di Rocco, Federico ; Vuillerot, Carole ; Held, Andrea ; Beuriat, Pierre Aurélien ; Dohin, Julie ; Mertens, Patrick ; Valayer, Emmanuel Chaleat ; Gordon, Xènia ; Lebedel, Nicolas ; de Laurentis, Camilla

BACKGROUND:

Intrathecal administration of Baclofen, a γ-aminobutyric acid agonist, is an established treatment for spasticity in both pediatric and adult populations, resulting in functional improvements in daily activities. Treatment optimization requires multiple, gradual dose adjustments to achieve the optimal dose for each patient, tailored to individualized goals and the specific pathology.

METHODS:

We conducted a retrospective review of our experience from August 2021 to December 2024. A total of 43 pediatric patients were implanted with an intrathecal Baclofen pump. We analyzed the test dose, the dose-finding process and the complications we experienced. Subsequently, we conducted a subgroup analysis to identify any statistically significant differences between subgroups.

RESULTS:

Thirty-five patients underwent a bolus via lumbar puncture, while in 6 cases via a subcutaneous reservoir. The average dose at the implantation was 69 mcg of baclofen/day ± 37 mcg/day, with an average dose change during the follow-up of +52% ± 79%. The cumulative revision rates were 6.9%, 7.7%, and 11.8% at 30 days, 3 months, and 6 months, respectively. No statistically significant differences between subgroups were found.

CONCLUSIONS:

The dose-finding requires a long and multistep process. The high interindividual variability highlights the need for a highly personalized approach to dose titration.

News (Medical) associated with Baclofen

21 Apr 2026

·www.biospace.com

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. “These important data in non-human primates together with previously reported guinea pig data demonstrates the therapeutic potential of our highly selective, orally available GABAB PAM,” said Tim Dyer, CEO of Addex. “Chronic cough is a difficult to treat disease in need of novel therapeutics with the efficacy of baclofen, which is used off-label in these patients, but without the dose limiting side effects. Based on the data generated to date, we believe our GABAB PAM drug candidate has this therapeutic pro the potential to be a once daily treatment for patients suffering from chronic cough.” In the NHP model of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency. In the same model, the antitussive efficacy of the GABAB PAM drug candidate was similar to that observed with baclofen. As previously reported, in the citric acid induced guinea pig model of chronic cough, the GABAB PAM drug candidate significantly reduced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound’s activity on respiratory rate. About GABAB activation and chronic cough The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed throughout the central and peripheral cough neural circuit as well as in the lungs and airways. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects including sedation, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound. About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit Contacts: Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@addextherapeutics.com Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@halsin.com Addex Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

15 Dec 2025

·www.businesswire.com

Trends Shaping the $5 Billion Spasticity Treatment Market, 2026-2034: Focus on Multimodal Care and Treatment Innovations - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Spasticity Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis" has been added to ResearchAndMarkets.com's offering. The global Spasticity Treatment Market, valued at USD 5.02 billion in 2025, is set to expand at a CAGR of 5.5%, reaching USD 8.13 billion by 2034. This growth is driven by innovations in pharmacologic therapies, interventional procedures, and multimodal rehabilitative modalities designed to manage spasticity associated with various neurological conditions. Key areas of focus include post-stroke rehabilitation, cerebral palsy, multiple sclerosis, spinal cord injuries, and traumatic brain injuries. The market is marked by a shift towards personalized treatment approaches, whereby oral antispasmodics, botulinum toxin injections, and intrathecal baclofen pumps are tailored to individual patient needs. Image-guided chemodenervation, device miniaturization, and remote monitoring are emerging trends enhancing treatment efficacy and patient outcomes. Key drivers of market growth include increased stroke survival rates, aging populations, improved diagnosis of pediatric neuromotor disorders, and payer recognition of treatments that reduce falls, contractures, and caregiver burden. Providers are distinguishing themselves through multidisciplinary clinics, reduced wait times, and protocolized treatments that emphasize measurable improvements in patient mobility and quality of life. In terms of regional insights, North America leads with comprehensive neurorehabilitation networks, Europe sees guideline-driven practices with strong focal injection adoption, and the Asia-Pacific region is expanding access due to rising MS awareness and growing pediatric neurology services. Meanwhile, Middle East & Africa and South & Central America are witnessing investments in rehabilitation infrastructure and caregiver education programs. The Spasticity Treatment Market segmented by type includes drug therapy, physical therapy, and surgical treatment, while end-users comprise hospitals, ambulatory surgical centers, specialty clinics, and diagnostic centers. Prominent market players include Amcor plc, Silgan Holdings, Inc., and Ardagh Group. The competitive space is characterized by strategic initiatives such as mergers, technology collaborations, and regional expansions that aim to advance product innovation and market reach. The report addresses market size forecasts, growth potential across segments, supply chain adaptations, and the impact of geopolitical shocks like the Russia-Ukraine conflict on trade and costs. Key Attributes Key Topics Covered 1. Table of Contents 2. Global Spasticity Treatment Market Summary, 2025 2.1 Spasticity Treatment Industry Overview 2.2 Spasticity Treatment Market Scope 2.3 Research Methodology 3. Spasticity Treatment Market Insights, 2024-2034 3.1 Spasticity Treatment Market Drivers 3.2 Spasticity Treatment Market Restraints 3.3 Spasticity Treatment Market Opportunities 3.4 Spasticity Treatment Market Challenges 3.5 Tariff Impact on Global Spasticity Treatment Supply Chain Patterns 4. Spasticity Treatment Market Analytics 4.1 Spasticity Treatment Market Size and Share 4.2 Five Forces Analysis for Global Spasticity Treatment Market 5. Global Spasticity Treatment Market Statistics 6. Asia Pacific Spasticity Treatment Industry Statistics 6.1 Asia Pacific Spasticity Treatment Market Insights 6.2 Asia Pacific Spasticity Treatment Market Revenue Forecast 6.3 Asia Pacific Spasticity Treatment Market Revenue Forecast by Country 7. Europe Spasticity Treatment Market Data 7.1 Europe Spasticity Treatment Market Key Findings 7.2 Europe Spasticity Treatment Market Size and Percentage Breakdown 7.3 Europe Spasticity Treatment Market Size and Percentage Breakdown by Country 8. North America Spasticity Treatment Market Size, Growth Trends, and Future Prospects 8.1 North America Snapshot 8.2 North America Spasticity Treatment Market Analysis and Outlook 8.3 North America Spasticity Treatment Market Analysis and Outlook by Country 9. South and Central America Spasticity Treatment Market Drivers, Challenges, and Future Prospects 9.1 Latin America Spasticity Treatment Market Data 9.2 Latin America Spasticity Treatment Market Future 9.3 Latin America Spasticity Treatment Market Future by Country 10. Middle East Africa Spasticity Treatment Market Outlook and Growth Prospects 10.1 Middle East Africa Overview 10.2 Middle East Africa Spasticity Treatment Market Statistics 10.3 Middle East Africa Spasticity Treatment Market Statistics by Country 11. Spasticity Treatment Market Structure and Competitive Landscape 11.1 Key Companies in Spasticity Treatment Industry 11.2 Spasticity Treatment Business Overview 11.3 Spasticity Treatment Product Portfolio Analysis 11.4 Financial Analysis 11.5 SWOT Analysis Key Companies Featured For more information about this report visit https://www.researchandmarkets.com/r/aj5h9l About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

12 May 2025

·www.globenewswire.com

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND enabling studies. This is the final preclinical development stage before clinical studies can be started. “Our partner Indivior has made great progress with their GABAB PAM substance use disorders program, successfully completing the last preclinical safety and toxicity studies with the compound they selected from our research collaboration. This significant achievement demonstrates the quality of the compounds discovered by the Addex team,” said Tim Dyer, CEO of Addex. “Our own GABAB PAM cough program is also advancing through preclinical studies and is scheduled to start IND enabling studies later this year.” As previously announced, Indivior has selected a GABAB PAM for future development in substance use disorders as part of a research collaboration between the two companies. Under the terms of the agreement, Addex is eligible for payments of up to USD 330 million on successful achievement of prespecified regulatory, clinical and commercial milestones as well as tiered royalties on the level of net sales from high single digits up to low double-digit. As part of the same agreement, Addex has selected a compound for it own independent GABAB PAM program and is advancing this program for the treatment of chronic cough. About GABAB Activation with PAM:Activation of gamma-aminobutyric acid subtype B (GABAB) receptor, a Family C class of GPCR, is clinically and commercially validated. The generic GABAB receptor agonist, baclofen, marketed for spasticity, has been shown to be efficacious in several other disease areas, including alcohol use disorder, CMT1A, overactive bladder, chronic cough and pain. However, its wider use is limited due to a variety of side effects, rapid clearance and the development of tolerance. Novel, potent, selective and orally available PAMs that potentiate GABA responses, rather than acting as orthosteric agonists at the GABAB receptor, like baclofen, are expected to deliver efficacy and have fewer adverse effects. Furthermore, PAMs only act when the natural ligand (GABA) activates the receptor, hence respecting the physiological cycle of activation, which may explain why PAMs lead to less tolerance than direct agonists. About Addex Therapeutics Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com Contacts: Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@addextherapeutics.com Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@halsin.com Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

License out/in

100 Deals associated with Baclofen

External Link

KEGG	Wiki	ATC	Drug Bank
D00241	Baclofen	M03BX01	DB00181

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Spinal Cord Diseases	United States	Metacel Pharmaceuticals LLC	18 Sep 2019
Spinal Cord Injuries	United States	Metacel Pharmaceuticals LLC	18 Sep 2019
Hereditary Spastic Paralysis, Infantile Onset Ascending	Japan	Daiichi Sankyo Co., Ltd.	11 Apr 2005
Multiple Sclerosis	United States	UCB, Inc.	30 Oct 2003
Muscle Spasticity	United States	Amneal Pharmaceuticals LLC	17 Jun 1992
Spastic paralysis	Japan	Sun Pharma Japan Ltd.	27 Aug 1979
Spastic paralysis	Japan	Alfresa Pharma Corp.	27 Aug 1979
Spasm	United States	Novartis Pharmaceuticals Corp.	22 Nov 1977

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alcoholism	Phase 3	France	Ethypharm SAS	01 Dec 2012
Chronic cough	Preclinical	Switzerland	Addex Therapeutics Ltd.	21 Apr 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04251819 (CTgov)	Phase 2/3	Analgesia \| Acute Pain	19	Placebos (Placebo)	fqgakrvfwo(cjdtekajyd) = afhfugdumm ncsdgymxsb (ovhcobfxff, 2.13) View more	-	07 Jan 2026
				Baclofen 5 mg (Baclofen 5mg)	fqgakrvfwo(cjdtekajyd) = dodmuiotov ncsdgymxsb (ovhcobfxff, 3.04) View more
EULAR2025	Not Applicable	Pain	181,677	Baclofen	bbwsfxlsqg(zrskkszpch) = gylzuawxyc vhttdzrsob (aixdicrqho ) View more	Positive	11 Jun 2025
				Cyclobenzaprine	bbwsfxlsqg(zrskkszpch) = bxotwaoxqx vhttdzrsob (aixdicrqho ) View more
NCT05161351 (FORWARDS-1, CTgov)	Phase 4	Heroin Dependence \| opioid dependence methadone	16	Vitamin D3	bymomwbjmt = xzstsymadb rvtveiycrt (ruvtvecuzi, ageqwjfwle - hjcvsypjjh) View more	-	18 Nov 2024
ACR2024	Not Applicable	Musculoskeletal Diseases	638,083	Cyclobenzaprine	hayxzeuvgo(czowaoskzn) = krmrndsopa oganvradfc (keznndzpcb ) View more	Similar	10 Nov 2024
				Baclofen	hayxzeuvgo(czowaoskzn) = attlyruvjp oganvradfc (keznndzpcb ) View more
NCT03720717 (CTgov)	Phase 4	Pain	34	Baclofen 10mg (Opioid Tolerant - Baclofen)	nzgrnquurg(khgysuciov) = gntktkuitz zbzgiwedic (tdgokvjulx, 33.6) View more	-	05 Sep 2024
				Placebo (Opioid Tolerant - Placebo)	nzgrnquurg(khgysuciov) = kokszqcecl zbzgiwedic (tdgokvjulx, 17.1) View more
NCT02998151 (CTgov)	Early Phase 1	Fragile X Syndrome	29	placebo (Placebo)	zjzbjgbggu(infnghbgdg) = gqzbehtcet kwpplpeupn (kaihffabhc, .0265) View more	-	24 Nov 2021
				Acamprosate (Acamprosate)	zjzbjgbggu(infnghbgdg) = gkyfnrtnwh kwpplpeupn (kaihffabhc, 0.0252) View more
NCT02723383 (Pubmed \| JAMA)	Phase 3	Alcoholism	314	Baclofen	gbsjlxwdqh(acfmtsyyid) = ththolyvwm vtprcpckjr (kebjjipgix ) View more	Positive	23 Feb 2021
				Placebo	gbsjlxwdqh(acfmtsyyid) = dvvjxvahgm vtprcpckjr (kebjjipgix ) View more
NCT03068897 (CTgov)	Phase 4	Low Back Pain	320	Educational intervention+Ibuprofen 600 mg+Metaxalone (Metaxalone)	puqgaivucq(xryvqbbmyd) = mfototeinx cyhebcokpy (dzytlrvibh, nzehmssucu - hyfjtbdxir) View more	-	12 Aug 2020
				Educational intervention+Ibuprofen 600 mg+Tizanidine (Tizanidine)	puqgaivucq(xryvqbbmyd) = xikuxwshdf cyhebcokpy (dzytlrvibh, krmsoarbfj - lbpcazlpvu) View more
ASN2019	Not Applicable	-	-	Baclofen ≥ 20 mg/day	boyixzigwt(knddhcrtab) = mtsmovsywt azyqzhyjou (kbcoobdjob )	Negative	05 Nov 2019
				Baclofen <20 mg/day	boyixzigwt(knddhcrtab) = perajqjalf azyqzhyjou (kbcoobdjob )
NCT01980706 (CTgov)	Phase 2	Alcoholism	120	Placebo (Placebo)	yeqsdxdyhj(mjjnuankhn) = diiroywwwb epiwuhcfop (exdvoenjuf, 4) View more	-	08 Jan 2019
				Baclofen (30 Mg Baclofen)	yeqsdxdyhj(mjjnuankhn) = gekxynzewc epiwuhcfop (exdvoenjuf, 4) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Baclofen

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation